Dr. Daniel Shasha, M.D., is a board-certified radiation oncologist specializing in genitourinary malignancies. He earned his medical degree from McGill University’s Faculty of Medicine and completed his residency at Memorial Sloan Kettering Cancer Center. With expertise in advanced oncological techniques like brachytherapy and image-guided radiation therapy, he is a respected leader in the oncology community, dedicated to innovation and patient-centered care.
Dr. Daniel Shasha, M.D., is a board-certified radiation oncologist specializing in genitourinary malignancies. He earned his medical degree from McGill University’s Faculty of Medicine and completed his residency at Memorial Sloan Kettering Cancer Center. With expertise in advanced oncological techniques like brachytherapy and image-guided radiation therapy, he is a respected leader in the oncology community, dedicated to innovation and patient-centered care.
Dr. Daniel Shasha, M.D., is a board-certified radiation oncologist specializing in the treatment of genitourinary malignancies, including prostate, bladder, renal, and testicular cancers, and palliative care. With expertise in advanced oncological techniques, including brachytherapy and image-guided radiation therapy, he employs cutting-edge methodologies to enhance precision and treatment efficacy.
He earned his medical degree from McGill University’s Faculty of Medicine in Canada and completed his residency at Memorial Sloan Kettering Cancer Center, where he trained under leading experts in the field.
Throughout his career, Dr. Shasha has been at the forefront of patient-centered oncology care, combining clinical excellence with a commitment to innovation. Beyond his practice, he has made significant contributions to oncology through active participation in clinical trials and research initiatives aimed at developing and validating novel therapeutic approaches.
Dedicated to lifelong learning and teaching, Dr. Shasha remains actively engaged in professional development, ensuring his practice reflects the latest advancements in oncological science. His commitment to evidence-based medicine and emerging therapies has established him as a respected leader in the oncology community.